CLDN11 and melanoma: For instance, Gao and colleagues showed that the promoter hypermethylation of Claudin 11 (CLDN11) can be used to discriminate between CM and dysplastic nevi, thus representing a potential melanoma-specific epigenetic biomarker [43].